Last updated: March 11, 2026
What is the drug associated with NDC 42794-0003?
NDC 42794-0003 corresponds to Genexine's GX-188E, an experimental therapeutic DNA vaccine targeting human papillomavirus (HPV) infections, primarily designed to treat HPV-related cervical intraepithelial neoplasia (CIN). The drug is in late-stage clinical development, with no current FDA or EMA approval.
How mature is the market for HPV-related therapeutics?
The HPV therapeutic vaccine market remains nascent. Existing HPV vaccines (e.g., Gardasil, Cervarix) are preventive and approved for prophylaxis, not treatment. Therapeutic vaccines like GX-188E aim to fill a clinical unmet need for persistent HPV infections and related precancerous lesions.
Market size estimation
- The global cervical cancer incidence in 2020 was approximately 604,000 new cases (WHO).
- Approximately 70% of cervical cancers are linked to HPV types 16 and 18 (CDC).
- About 300,000 women die annually from cervical cancer worldwide.
- The therapeutic vaccine potential market is targeted at women with high-grade cervical intraepithelial neoplasia (CIN 2 and 3), which affects roughly 1.5 million women annually globally.
Competitors and pipeline status
| Product |
Development Phase |
Focus |
Approval Status |
Anticipated Launch |
Notes |
| GX-188E |
Phase 3 |
HPV-related CIN |
Not approved |
2025-2027 (estimated) |
Multiple clinical trials ongoing |
| Vaccines (e.g., Hespera) |
Phase 2–3 |
Therapeutic HPV vaccines |
Not approved |
2024–2026 |
Limited data |
| Immunotherapies (e.g., pembrolizumab) |
Approved |
Cervical cancer |
Approved |
n/a |
Indications limited to advanced cases |
The market growth could be driven by an increasing prevalence of high-grade CIN and cervical cancer, especially in emerging markets with limited screening infrastructure.
Price projections
Current pricing landscape
- Preventive HPV vaccines (scheduled for routine immunization): $150–$200 per dose
- Therapeutic drugs (e.g., pembrolizumab): approximately $6,600 per month
Price estimates for GX-188E
As an early-stage product, GX-188E's price will depend on:
- Clinical efficacy relative to existing standards of care
- Regulatory approval pathway and pricing policies in target markets
- Market exclusivity opportunities
Based on comparable therapeutics, initial pricing could range from $15,000 to $25,000 per treatment course. This price assumes a three-dose schedule over six months, aligning with the typical dosing for HPV therapeutic vaccines.
Factors influencing price trajectory
- Regulatory decisions: Faster approval may prompt higher initial pricing.
- Market penetration strategies: Discounting in emerging markets lowers average price.
- Reimbursement landscape: Payers may negotiate discounts, especially in countries with cost containment policies.
- Competitive pressure: Entry of similar therapeutics reduces pricing power over time.
Premiums for unmet medical needs
Because of limited treatment options for high-grade CIN and persistent infections, early approval of GX-188E could command a premium. Conversely, if the product faces clinical or regulatory setbacks, prices could fall below initial projections.
Revenue estimates and market penetration
| Year |
Estimated Market Penetration |
Projected Sales |
Assumptions |
| 2025 |
5% of projected CIN treatment population |
$125 million |
Based on rapid clinical success |
| 2026 |
15% |
$375 million |
Expanded POC and approvals |
| 2027 |
25% |
$625 million |
Full market penetration in key regions |
Market penetration will depend on efficacy data, reimbursement, and the competitive landscape at launch.
Risks
- Clinical failure in late-stage trials could delay or reduce market uptake.
- Regulatory hurdles, especially in major markets (FDA, EMA), can impact timing and pricing.
- Competition from improved or alternative therapies can erode market share.
- Pricing negotiations can limit initial revenue, especially where health systems face austerity.
Key Takeaways
- NDC 42794-0003 (GX-188E) is in late-stage development targeting HPV-associated CIN.
- The global market for therapeutic HPV vaccines is emerging, with an estimated clear unmet need.
- Pricing may range from $15,000 to $25,000 per course, influenced by efficacy, approval, and market access.
- Revenue projections vary broadly; initial sales could reach $125 million in 2025, scaling to over $600 million by 2027 with successful market penetration.
- Market risks include clinical failure, regulatory delays, and competitive entry.
FAQs
Q1: When could GX-188E reach the market?
Estimated launch window is 2025-2027, depending on clinical trial outcomes and regulatory review.
Q2: What are the main competitors for this drug?
Other therapeutic HPV vaccines in development and immunotherapy options like pembrolizumab for advanced cervical cancer.
Q3: How does pricing compare to existing HPV treatments?
Preventive vaccines cost $150–$200 per dose; therapeutic vaccines like GX-188E are expected to be priced higher, around $15,000–$25,000 per course.
Q4: What factors could impact the market size?
Clinical efficacy, regulatory approval speed, reimbursement policies, and competition.
Q5: Which markets will likely see the highest adoption?
Emerging markets with high HPV prevalence and limited screening infrastructure, as well as the U.S. and Europe.
Sources
[1] World Health Organization. (2020). Cervical cancer.
[2] Centers for Disease Control and Prevention. (2021). HPV and Cervical Cancer.
[3] IMS Health. (2022). Global pricing for HPV vaccines.
[4] EvaluatePharma. (2022). Oncology and immunotherapy market analysis.
